Intellia Therapeutics (NTLA) Operating Expenses (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Operating Expenses data on file, last reported at $115.6 million in Q1 2026.

• Quarterly Operating Expenses fell 15.9% year-over-year to $115.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $486.8 million (down 17.02% YoY) and the FY2025 annual result came in at $508.7 million, down 14.1% from the prior year.
• Operating Expenses eased to $115.6 million in Q1 2026 per NTLA's latest filing, from $121.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $155.5 million in Q1 2022 and bottomed at $112.3 million in Q2 2022.
• The 5-year median for Operating Expenses is $137.4 million (2025), against an average of $134.0 million.
• The widest annual swing landed in 2022, when Operating Expenses jumped 194.11%; it then decreased 19.89% in 2023.
• Tracing NTLA's Operating Expenses over 5 years: stood at $123.7 million in 2022, then increased by 11.58% to $138.0 million in 2023, then advanced by 8.22% to $149.3 million in 2024, then dropped by 18.48% to $121.7 million in 2025, then dropped by 5.05% to $115.6 million in 2026.
• Per Business Quant, the three latest NTLA Operating Expenses figures stand at $115.6 million (Q1 2026), $121.7 million (Q4 2025), and $125.3 million (Q3 2025).

Peer Comparison